Evidence map›Paper›PMID 42620773›Full record

ArticleFrontiers in oncology2026

Concurrent icotinib and definitive radiotherapy followed by detection of an EGFR exon 20 insertion at disease progression in unresectable stage III EGFR S768I-mutant lung adenocarcinoma: a case report.

Bingyue Wang, Yangchenxi Wang, Hongyuan Liu, Kaiyue Wang, Xiaona Chang, Sheng Zhang, Zhendong Dai, Chuangyan Wu, Rui Zhou

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Bingyue WangCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yangchenxi WangCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hongyuan LiuCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Kaiyue WangCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xiaona ChangDepartment of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Sheng ZhangCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zhendong DaiDepartment of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Chuangyan WuDepartment of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Rui ZhouCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Uncommon EGFR mutations account for approximately 10-15% of all EGFR-mutated non-small cell lung cancer (NSCLC), and the optimal management of unresectable stage III disease harboring isolated EGFR S768I mutations remains poorly defined. We report the case of a 55-year-old woman with unresectable stage IIIC lung adenocarcinoma harboring an isolated EGFR S768I mutation. Because platinum-based chemotherapy was discontinued owing to severe gastrointestinal toxicity, she received concurrent icotinib and definitive intensity-modulated radiotherapy (IMRT), achieving a partial response with a progression-free survival of approximately 8 months and only grade 1 oral mucositis. At disease progression, repeat biopsy followed by next-generation sequencing (NGS) identified an EGFR exon 20 insertion (p.V769_D770insSVV) together with a marked reduction in the abundance of the original EGFR S768I mutation. As comprehensive baseline genomic profiling was unavailable, these findings should be interpreted cautiously and may represent either treatment-associated molecular alteration or expansion of a pre-existing low-frequency resistant subclone rather than definitive acquisition of a new mutation. Subsequent treatment with afatinib, ivonescimab plus chemotherapy, and sunvozertinib was selected according to dynamic molecular profiling. This case suggests that concurrent icotinib and definitive radiotherapy may represent a feasible individualized treatment option for carefully selected patients with unresectable stage III EGFR-mutant NSCLC who are unable to tolerate standard concurrent chemoradiotherapy. More importantly, it highlights the value of repeat biopsy and comprehensive genomic profiling for interpreting molecular changes at disease progression and guiding subsequent individualized treatment in patients with uncommon EGFR mutations. However, these observations are derived from a single case and require validation in larger prospective studies.

Indexed as

case reportconcurrent radiotherapyEGFR S768I mutationicotinibNSCLCPACC mutation

Identifiers

PMID42620773
PMCPMC13485718

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.